



PRODUCT: **GIVLAARI®**

COMPANY: Alnylam Pharmaceuticals

THERAPEUTIC AREA & INDICATION:

Acute hepatic porphyria (AHP) linked
to production of toxic porphyrin
molecules in the bloodstream in adults

ABOUT THE PRODUCT

The first-ever FDA-approved oligonucleotide therapeutic using GalNAc conjugate technology and second-ever FDA-approved RNA interference (RNAi) therapeutic, GIVLAARI® (givosiran) further validates Nobel-Prize winning RNAi science as a groundbreaking platform for the development of therapeutics for complex, serious conditions with limited treatment options.

GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP)—a family of rare genetic diseases characterized by potentially life-threatening attacks and, for some people, chronic debilitating symptoms that negatively impact daily functioning and quality of life.